Literature DB >> 30480868

Increase of scabies in Germany and development of resistant mites? Evidence and consequences.

Cord Sunderkötter1,2, Anton Aebischer3, Matthias Neufeld2, Christoph Löser4, Alexander Kreuter5, Ralf Bialek6, Henning Hamm7, Hermann Feldmeier8.   

Abstract

Scabies has been diagnosed surprisingly frequently in Germany in recent years, and the use of acaricides has risen markedly. Present figures indicate an increase in the prevalence/incidence of scabies, but do not prove or quantify it for the following reasons: (a) scabies is not a notifiable disease in Germany; (b) the diagnosis is not always confirmed lege artis by means of light microscopy or dermatoscopy (which may lead to a comparatively high proportion of false‐positive diagnoses due to the low overall prevalence of scabies); (c) repeated treatments of the same patient and treatment of contact persons are included in the total number of prescriptions. Therefore, there are no valid data on disease occurrence, either in the current situation or from previous periods. Observations of ineffective treatment with permethrin have led to speculations that Sarcoptes mites are developing resistance to this drug. However, there is little evidence for this assumption. We discuss risk groups (children, elderly people in need of care, migrant health personnel in nursing institutions, refugees, sexually active young adults) and evaluate their possible contribution, albeit in the absence of evidence. None of the groups would be solely responsible for an increased frequency. We have compiled recommendations on how the management of scabies could be improved, and present a way of differentiating permethrin resistance from application errors and/or lack of compliance. The goal is to solve the epidemiological and parasitological questions mentioned above.
© 2018 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30480868     DOI: 10.1111/ddg.13706

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  8 in total

1.  Increasing incidence of reported scabies infestations in the Netherlands, 2011-2021.

Authors:  Babette van Deursen; Mariëtte Hooiveld; Susan Marks; Ingrid Snijdewind; Hans van den Kerkhof; Bas Wintermans; Ben Bom; Barbara Schimmer; Ewout Fanoy
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

Review 2.  Scabies: Epidemiology, Diagnosis, and Treatment.

Authors:  Cord Sunderkötter; Johannes Wohlrab; Henning Hamm
Journal:  Dtsch Arztebl Int       Date:  2021-10-15       Impact factor: 8.251

3.  Erythrodermic scabies in an immunocompetent patient.

Authors:  Ronan Talty; Goran Micevic; William Damsky; Brett A King
Journal:  JAAD Case Rep       Date:  2022-09-08

4.  An Emollient Containing Aquaphilus dolomiae Extract is Effective in the Management of Xerosis and Pruritus: An International, Real-World Study.

Authors:  Mette Deleuran; Victor Georgescu; Catherine Jean-Decoster
Journal:  Dermatol Ther (Heidelb)       Date:  2020-07-14

5.  Increase of scabies infestations, Norway, 2006 to 2018.

Authors:  E Amato; L S Dansie; G M Grøneng; H S Blix; H Bentele; L Veneti; P Stefanoff; E MacDonald; H H Blystad; A Soleng
Journal:  Euro Surveill       Date:  2019-06

6.  Epidemiologic evolution of common cutaneous infestations and arthropod bites: A Google Trends analysis.

Authors:  Thierry Simonart; Xuân-Lan Lam Hoai; Viviane De Maertelaer
Journal:  JAAD Int       Date:  2021-09-02

7.  The national burden of scabies in Germany: a population-based approach using Internet search engine data.

Authors:  Jing Wu; Linda Tizek; Melvin Rueth; Hannah Wecker; Alphina Kain; Tilo Biedermann; Alexander Zink
Journal:  Infection       Date:  2022-02-08       Impact factor: 7.455

8.  Scabies in Spain? A comprehensive epidemiological picture.

Authors:  Lidia Redondo-Bravo; Beatriz Fernandez-Martinez; Diana Gómez-Barroso; Alin Gherasim; Montserrat García-Gómez; Agustín Benito; Zaida Herrador
Journal:  PLoS One       Date:  2021-11-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.